S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NYSE:IKT

Inhibikase Therapeutics (IKT) Stock Forecast, Price & News

$1.39
-0.05 (-3.47%)
(As of 09/29/2023 ET)
Compare
Today's Range
$1.36
▼
$1.49
50-Day Range
$1.01
▼
$2.60
52-Week Range
$0.95
▼
$6.94
Volume
34,349 shs
Average Volume
47,406 shs
Market Capitalization
$7.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media

Inhibikase Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,842.4% Upside
$27.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.39) to ($4.33) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

See Top Rated MarketRank™ Stocks Here

IKT stock logo

About Inhibikase Therapeutics (NYSE:IKT) Stock

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

IKT Price History

IKT Stock News Headlines

September 20, 2023 | finance.yahoo.com
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
August 24, 2023 | finance.yahoo.com
Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib
September 29, 2023 | Chaikin Analytics (Ad)
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
August 21, 2023 | finance.yahoo.com
Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib
August 18, 2023 | markets.businessinsider.com
Inhibikase Therapeutics (IKT) Gets a Hold from JonesTrading
August 17, 2023 | markets.businessinsider.com
Inhibikase: 600 Mg IkT-001Pro Shows Bioequivalence To 400 Mg Dose Of Imatinib Mesylate
August 17, 2023 | finance.yahoo.com
Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro
August 16, 2023 | msn.com
HC Wainwright & Co. Reiterates Inhibikase Therapeutics (IKT) Buy Recommendation
September 29, 2023 | Chaikin Analytics (Ad)
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
August 16, 2023 | finance.yahoo.com
Q2 2023 Inhibikase Therapeutics Inc Earnings Call
August 15, 2023 | finanznachrichten.de
Inhibikase Therapeutics, Inc.: Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
August 14, 2023 | finance.yahoo.com
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
July 17, 2023 | finance.yahoo.com
Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements
July 6, 2023 | msn.com
Inhibikase Therapeutics (IKT) Price Target Increased by 440.00% to 27.54
July 1, 2023 | finanznachrichten.de
Inhibikase Therapeutics, Inc.: Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
June 30, 2023 | nasdaq.com
HC Wainwright & Co. Maintains Inhibikase Therapeutics (IKT) Buy Recommendation
June 29, 2023 | finance.yahoo.com
Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
June 22, 2023 | finance.yahoo.com
Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study
June 21, 2023 | finance.yahoo.com
Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease
May 30, 2023 | finance.yahoo.com
Inhibikase Therapeutics to Present at the LD Micro Invitational XIII
May 24, 2023 | finance.yahoo.com
Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology
May 17, 2023 | finance.yahoo.com
Inhibikase Therapeutics First Quarter 2023 Earnings: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022)
May 16, 2023 | finance.yahoo.com
Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
May 15, 2023 | finanznachrichten.de
Inhibikase Therapeutics, Inc.: Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
May 15, 2023 | finance.yahoo.com
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
May 8, 2023 | finance.yahoo.com
Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023
May 4, 2023 | finance.yahoo.com
Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
See More Headlines
Receive IKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IKT Company Calendar

Last Earnings
8/14/2023
Today
9/29/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:IKT
CUSIP
N/A
CIK
1750149
Web
www.inhibikase.com
Phone
678-392-3419
Fax
N/A
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.00
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+1,842.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.1694)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-18,050,000.00
Net Margins
-7,551.59%
Pretax Margin
-7,551.19%
Return on Equity
-83.69%
Return on Assets
-73.17%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.04
Quick Ratio
8.04

Sales & Book Value

Annual Sales
$120,000.00
Price / Sales
61.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.50 per share
Price / Book
0.31

Miscellaneous

Outstanding Shares
5,350,000
Free Float
4,262,000
Market Cap
$7.44 million
Optionable
Not Optionable
Beta
0.79
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Milton H. Werner Ph.D. (Age 59)
    CEO, Pres & Director
    Comp: $658.19k
  • Mr. Joseph Frattaroli CPA (Age 61)
    Chief Financial Officer
    Comp: $531.83k
  • Dr. Roger Rush
    Head of Preclinical Research
  • Dr. Surendra Singh
    Head of Chemistry, Manufacturing & Controls
  • Dr. Charles Warren Olanow B.Sc.
    F.R.C.P.C., M.D., CEO of Clintrex Research Corp. & Member of Scientific Advisory Board
  • Dan Williams
    Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













IKT Stock - Frequently Asked Questions

Should I buy or sell Inhibikase Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inhibikase Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IKT shares.
View IKT analyst ratings or view top-rated stocks.

What is Inhibikase Therapeutics' stock price forecast for 2023?

2 brokers have issued 1 year target prices for Inhibikase Therapeutics' stock. Their IKT share price forecasts range from $27.00 to $27.00. On average, they expect the company's share price to reach $27.00 in the next twelve months. This suggests a possible upside of 1,842.4% from the stock's current price.
View analysts price targets for IKT or view top-rated stocks among Wall Street analysts.

How have IKT shares performed in 2023?

Inhibikase Therapeutics' stock was trading at $3.00 at the beginning of 2023. Since then, IKT shares have decreased by 53.7% and is now trading at $1.39.
View the best growth stocks for 2023 here.

When is Inhibikase Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our IKT earnings forecast.

How were Inhibikase Therapeutics' earnings last quarter?

Inhibikase Therapeutics, Inc. (NYSE:IKT) released its quarterly earnings results on Monday, August, 14th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by $0.19. The firm earned $0.12 million during the quarter. Inhibikase Therapeutics had a negative net margin of 7,551.59% and a negative trailing twelve-month return on equity of 83.69%.

When did Inhibikase Therapeutics' stock split?

Shares of Inhibikase Therapeutics reverse split on the morning of Friday, June 30th 2023. The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

When did Inhibikase Therapeutics IPO?

(IKT) raised $15 million in an initial public offering (IPO) on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity​ (a division of Fordham Financial Management) served as the underwriter for the IPO.

What is Inhibikase Therapeutics' stock symbol?

Inhibikase Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "IKT."

How do I buy shares of Inhibikase Therapeutics?

Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inhibikase Therapeutics' stock price today?

One share of IKT stock can currently be purchased for approximately $1.39.

How much money does Inhibikase Therapeutics make?

Inhibikase Therapeutics (NYSE:IKT) has a market capitalization of $7.44 million and generates $120,000.00 in revenue each year. The company earns $-18,050,000.00 in net income (profit) each year or ($4.1694) on an earnings per share basis.

How can I contact Inhibikase Therapeutics?

The official website for the company is www.inhibikase.com. The company can be reached via phone at 678-392-3419 or via email at alex.lobo@sternir.com.

This page (NYSE:IKT) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -